DalCor Pharmaceuticals
DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease through precision medicine. They aim to deliver dalcetrapib, the first pharmacogenetic precision medicine targeting patients with the AA genotype at rs1967309 in the ADCY9 gene. Their clinical trials, including dal-GenE and dal-GenE-2, evaluate the efficacy of dalcetrapib in reducing myocardial infarction in genetically targeted populations. The company holds exclusive rights to develop, manufacture, and commercialize dalcetrapib and its genetic marker, with a companion diagnostic developed in partnership with Roche. DalCor's mission is to improve cardiovascular outcomes by leveraging genetic insights.
Industries
Nr. of Employees
small (1-50)
DalCor Pharmaceuticals
2001 Boulevard Robert Bourassa, Suite 1700, Montreal, Quebec H3A 2A6
Products
Dalcetrapib (investigational pharmacogenetic therapy)
An investigational therapeutic under development for reduction of fatal and non-fatal myocardial infarction in patients who carry a specific ADCY9 rs1967309 AA genotype; evaluated in large Phase III outcomes trials.
ADCY9 rs1967309 genotype companion diagnostic
A genotyping assay intended to identify patients with the ADCY9 rs1967309 AA genotype to enable enrollment in genotype-guided therapeutic programs.
Dalcetrapib (investigational pharmacogenetic therapy)
An investigational therapeutic under development for reduction of fatal and non-fatal myocardial infarction in patients who carry a specific ADCY9 rs1967309 AA genotype; evaluated in large Phase III outcomes trials.
ADCY9 rs1967309 genotype companion diagnostic
A genotyping assay intended to identify patients with the ADCY9 rs1967309 AA genotype to enable enrollment in genotype-guided therapeutic programs.
Services
Planning and execution of a Phase III, double-blind, randomized, placebo-controlled cardiovascular outcomes trial in genotype-selected patients, including interim efficacy analysis and multinational site coordination.
Deployment and use of a genotyping assay to identify patients carrying a specific ADCY9 genotype for inclusion in precision-medicine clinical programs; includes collaboration management with diagnostics developers.
Planning and execution of a Phase III, double-blind, randomized, placebo-controlled cardiovascular outcomes trial in genotype-selected patients, including interim efficacy analysis and multinational site coordination.
Deployment and use of a genotyping assay to identify patients carrying a specific ADCY9 genotype for inclusion in precision-medicine clinical programs; includes collaboration management with diagnostics developers.
Expertise Areas
- Clinical trial management (Phase III cardiovascular outcomes)
- Pharmacogenetics and precision medicine
- Cardiovascular drug development
- Companion diagnostic integration and validation
Key Technologies
- Pharmacogenetic stratification
- Genotyping assays for ADCY9 rs1967309
- Companion diagnostic assays
- Randomized double-blind placebo-controlled trial methodology
News & Updates
The trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and the AA genotype at rs1967309 in the ADCY9 gene.
DalCor Pharmaceuticals announced that the dal-GenE trial will continue as planned following an independent Data and Safety Monitoring Board recommendation.
DalCor announced the closing of an $80 million USD Series D financing round to conduct the Dal-GenE-2 confirmatory trial in North America under an SPA with the FDA.
DalCor announced the closing of an $80 million USD Series D financing round to conduct the Dal-GenE-2 confirmatory trial in North America under an SPA with the FDA.
The trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and the AA genotype at rs1967309 in the ADCY9 gene.
The trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and the AA genotype at rs1967309 in the ADCY9 gene.
DalCor Pharmaceuticals announced that the dal-GenE trial will continue as planned following an independent Data and Safety Monitoring Board recommendation.
DalCor announced the closing of an $80 million USD Series D financing round to conduct the Dal-GenE-2 confirmatory trial in North America under an SPA with the FDA.
DalCor announced the closing of an $80 million USD Series D financing round to conduct the Dal-GenE-2 confirmatory trial in North America under an SPA with the FDA.
The trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and the AA genotype at rs1967309 in the ADCY9 gene.